biostudies-literatureUnknown9(1)Madaci LADEREM, Marseille, FranceAfter decades during which the treatment of acute myeloblastic leukemia was limited to variations around a skeleton of cytarabine/anthracycline, targeted therapies appeared. These therapies, first based on monoclonal antibodies, also rely on specific inhibitors of various molecular abnormalities. A significant but modest prognosis improvement has been observed thanks to these new treatments that are limited by a high rate of relapse, due to the intrinsic chemo and immune-resistance of leukemia stem cell, together with the acquisition of these resistances by clonal evolution. Relapses are also influenced by the equilibrium between the pro or anti-tumor signals from the bone marrow stromal microenvironment and immune effectors. What should be the place of the targeted therapeutic options in Biomarker research50https://www.ebi.ac.uk/biostudies/studies/S-EPMC8237443biostudies-literatureThe contribution of single-cell analysis of acute leukemia in the therapeutic strategy.PMC8237443Loriod BMadaci LCostello RColle JVenton GFarnault LfalseThe contribution of single-cell analysis of acute leukemia in the therapeutic strategy.After decades during which the treatment of acute myeloblastic leukemia was limited to variations around a skeleton of cytarabine/anthracycline, targeted therapies appeared. These therapies, first based on monoclonal antibodies, also rely on specific inhibitors of various molecular abnormalities. A significant but modest prognosis improvement has been observed thanks to these new treatments that are limited by a high rate of relapse, due to the intrinsic chemo and immune-resistance of leukemia stem cell, together with the acquisition of these resistances by clonal evolution. Relapses are also influenced by the equilibrium between the pro or anti-tumor signals from the bone marrow stromal microenvironment and immune effectors. What should be the place of the targeted therapeutic options in 2021-01-01T00:00:00Z2021 Jun2025-04-04T09:10:42.293Z2022-02-10T17:44:05.918ZS-EPMC82374433417651710.1186/s40364-021-00300-0